ExploreWatchlistsPricing
  1. JP-listed companies
  2. Cuorips Inc.
  3. Financials
  4. Net income

Cuorips Inc. (4894)

Market cap
¥38.2B
P/E ratio
-27.4x
Qualips develops regenerative medicine treatments using human iPS cells, specializing in cardiac muscle cell sheets for severe heart failure patients.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Mar 31, 2026-1,023+58.71%
Mar 31, 2025-644+1.92%
Mar 31, 2024-632+39.84%
Mar 31, 2023-452+20.45%
Mar 31, 2022-375+21.93%
Mar 31, 2021-308+71.18%
Mar 31, 2020-180+40.22%
Mar 31, 2019-128+383.18%
Mar 31, 2018-27

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat